Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1989 Jul;7(2-3):213-8.
doi: 10.1007/BF00170860.

Phase I and pharmacokinetic study of SM-5887, a new anthracycline derivative

K Inoue  1 , M Ogawa, N Horikoshi, T Mukaiyama, Y Itoh, K Imajoh, H Ozeki, D Nagamine, K Shinagawa
Affiliations

Phase I and pharmacokinetic study of SM-5887, a new anthracycline derivative

K Inoue et al. Invest New Drugs. 1989 Jul.

Abstract

SM-5887, a new totally synthetic anthracycline derivative was studied in a phase I setting. Twenty-nine evaluable courses of treatment were conducted in groups at doses increasing from 10 to 130 mg/m2. Myelosuppression was the dose-limiting toxicity and a MTD was 130 mg/m2. At 130 mg/m2 the median lowest white blood cell count was 0.7 x 10(3)/cmm (range: 0.3-1.8) and the median lowest granulocyte count was 0.1 x 10(3)/cmm (range: 0-0.7) and the median lowest platelet count was 57 x 10(3)/cmm (range: 4-176). Non-hematologic side effects were mild gastrointestinal symptoms and hair loss. The recommended dose and schedule for phase II setting is 100 mg/m2 every 3 weeks.

PubMed Disclaimer

References

    1. Gan To Kagaku Ryoho. 1986 Feb;13(2):261-70 - PubMed
    1. Biomedicine. 1973 Apr 10;19(4):169-71 - PubMed
    1. Clin Pharmacol Ther. 1973 Jul-Aug;14(4):592-600 - PubMed
    1. J Pharmacobiodyn. 1981 Nov;4(11):879-85 - PubMed